Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Michael P. Diamond(Augusta University), Kristof Chwalisż(AbbVie (United States)), Joshua Burke(Neurocrine Biosciences (United States)), Ping Jiang(AbbVie (United States)), Bruce R. Carr(University of Florida), Roland Jimenez(Neurocrine Biosciences (United States)), Elizabeth Garner(American Association of University Women), C. F. O'Brien(Neurocrine Biosciences (United States)), W. Paul Dmowski(Creighton University), William Koltun(Center for Clinical Research (United States))
Cited by 120
Related Papers
Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations
|Nature Communications|2015|542
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
|New England Journal of Medicine|2017|492
Deficient cellular immunity in endometriosis
|American Journal of Obstetrics and Gynecology|1981|310
Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis
|Fertility and Sterility|1996|270
Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis
|Human Reproduction|2001|232